Related Experiment Video
Updated: Feb 1, 2026

A Permanent Window for Investigating Cancer Metastasis to the Lung
Published on: July 1, 2021
MiR-520b inhibited metastasis and proliferation of non-small cell lung cancer by targeting CHAF1A
1Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. jijuxiebaby@aliyun.com.
Objective:
To investigate the potential effect of miR-520b on the development of non-small cell lung cancer and to explore the underlying mechanism.
Patients And Methods:
The expression levels of miR-520b in non-small cell lung cancer (NSCLC) tissues and cells (A549), as well as corresponding adjacent normal tissues and normal human lung epithelial cells (BEAS-2B), were detected by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR), respectively. Luciferase reported gene assay was performed to evaluate the interaction between miR-520b and chromatin assembly factor 1 subunit A (CHAF1A). Meanwhile, the effect of the miR-520b/CHAF1A axis on A549 cells was determined by subsequent experiments, including CHAF1A expression detection, cell proliferation, migration and invasion.
Results:
MiR-520b was lowly expressed in NSCLC tissues than that of corresponding adjacent normal tissues. Same results were obtained at the cellular level. To investigate the potential targets of miR-520b, we searched three publicly available algorithms, including TargetScan, miRDB and microRNA. Results indicated that CHAF1A was a direct target of miR-520b. Meanwhile, the luciferase reporter gene assay confirmed our hypothesis. Subsequent experiments demonstrated that decreased expression of CHAF1A resulting from the up-regulation of miR-520b could decelerate the proliferation, invasion and migration of lung cancer cells.
Conclusions:
We discovered the inhibitory function of miR-520b in NSCLC by targeting CHAF1A. Moreover, our study revealed that the miR-520b/CHAF1A axis might be a potential therapeutic target for the treatment of NSCLC.
Insights
MicroRNA-520b (miR-520b) inhibits non-small cell lung cancer (NSCLC) development by targeting CHAF1A. This miR-520b/CHAF1A pathway presents a potential therapeutic target for NSCLC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Gene Regulation
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide.
- Understanding the molecular mechanisms underlying NSCLC development is crucial for identifying effective therapeutic targets.
- MicroRNAs (miRNAs) play significant roles in cancer progression, including NSCLC.
Purpose of the Study:
- To investigate the role of miR-520b in the development of non-small cell lung cancer (NSCLC).
- To elucidate the underlying molecular mechanism of miR-520b action in NSCLC.
- To explore the potential of the miR-520b/CHAF1A axis as a therapeutic target for NSCLC.
Main Methods:
- Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) to measure miR-520b expression in NSCLC and normal tissues/cells.
- Luciferase reporter gene assay to confirm the direct interaction between miR-520b and CHAF1A.
- Assessment of CHAF1A expression, cell proliferation, migration, and invasion following modulation of the miR-520b/CHAF1A axis.
Main Results:
- MiR-520b expression was significantly downregulated in NSCLC tissues and cells compared to normal controls.
- Chromatin assembly factor 1 subunit A (CHAF1A) was identified as a direct target of miR-520b.
- Upregulation of miR-520b led to decreased CHAF1A expression, consequently inhibiting NSCLC cell proliferation, migration, and invasion.
Conclusions:
- MiR-520b exhibits an inhibitory function in NSCLC by directly targeting CHAF1A.
- The miR-520b/CHAF1A axis represents a promising therapeutic target for the treatment of non-small cell lung cancer.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Feedback Inhibition
Cells Coordinate Growth and Proliferation
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Abnormal Proliferation
Lung Capacity

